ConductScience.org, home

Paper39304595

Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice.

Mahmood I. Eur J Drug Metab Pharmacokinet, 2024. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice. Papers, record 39304595. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39304595

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice.
PubMed
Journal
Eur J Drug Metab Pharmacokinet
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.13, provisional
iCite
Revised in PubMed
2026-11-01
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mahmood IIftekharhttps://orcid.org/0000-0003-1311-4237

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Chimeric AntigenMajor topic
Immunotherapy, AdoptiveMajor topic
Animals
Mice
Humans
Body Weight
T-Lymphocytes

Source PubMed

Download CSV of topics

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133632155Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.BMC Cancer2021https://conductscience.org/library/papers/33632155PubMed
29336307The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.J Pharmacol Exp Ther1997https://conductscience.org/library/papers/9336307PubMed
38378254Physiological parameters in laboratory animals and humans.Pharm Res1993https://conductscience.org/library/papers/8378254PubMed
432042751Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice.Ann Transl Med2019https://conductscience.org/library/papers/32042751PubMed
58568013First-time-in-human dose selection: allometric thoughts and perspectives.J Clin Pharmacol1995https://conductscience.org/library/papers/8568013PubMed
634562983A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey.Antibodies (Basel)2021https://conductscience.org/library/papers/34562983PubMed
719837907Interspecies scaling of therapeutic monoclonal antibodies: initial look.J Clin Pharmacol2009https://conductscience.org/library/papers/19837907PubMed
816172177How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.J Clin Pharmacol2005https://conductscience.org/library/papers/16172177PubMed
933430196Interspecies Scaling of Antibody-Drug Conjugates (ADC) for the Prediction of Human Clearance.Antibodies (Basel)2021https://conductscience.org/library/papers/33430196PubMed
1019177515Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation.J Pharm Sci2009https://conductscience.org/library/papers/19177515PubMed
1132755128
Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients
Turk J Haematol2020https://conductscience.org/library/papers/32755128PubMed
1211936701Estimating the starting dose for entry into humans: principles and practice.Eur J Clin Pharmacol2002https://conductscience.org/library/papers/11936701PubMed
1312861964Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance.J Clin Pharmacol2003https://conductscience.org/library/papers/12861964PubMed
1433753909Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.Gene Ther2021https://conductscience.org/library/papers/33753909PubMed
156396053Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.Drug Metab Rev1984https://conductscience.org/library/papers/6396053PubMed
1635848614Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical ApplicationTurk J Haematol2022https://conductscience.org/library/papers/35848614PubMed
1728039267Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.Clin Cancer Res2017https://conductscience.org/library/papers/28039267PubMed
1825505964Clinical application of genetically modified T cells in cancer therapy.Clin Transl Immunology2014https://conductscience.org/library/papers/25505964PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
41884842Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Front Immunol2026https://conductscience.org/library/papers/41884842

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39304595

GET https://conductscience.org/api/papers/v1/39304595/authors